The Big Pharma is paying $30 million upfront to pick up the rights to the program and take it into the clinic.

Newly minted CEO Vas Narasimhan is paying a hefty premium to establish Novartis as a frontrunner in the emerging gene therapy sector.

The $400 million deal gives Novo worldwide rights to an epigenetic treatment of the disease that is closing in on the start of a phase 2 trial.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Six months after getting off its series A, Kymera Therapeutics has nabbed a deal with GlaxoSmithKline, although exact details are under wraps.

Roche snapped up a remyelinating drug candidate for multiple sclerosis from an alliance with Versant that also spawned startup Pipeline Therapeutics.

The Terns deal is a poster child of "Lilly China Innovation and Partnerships," a new model in place of Lilly's Shanghai R&D center shuttered…

After selling Kite for $11.9 billion, former executives Arie Belldegrun and David Chang are working on off-the-shelf CAR-T.